Published in Hepatology on February 20, 2014
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology (2014) 1.16
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology (2015) 1.11
Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2015) 1.06
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy (2016) 0.96
Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma. Int J Clin Exp Pathol (2015) 0.86
Antitumor CD8+ T cells in hepatocellular carcinoma: present but exhausted. Hepatology (2014) 0.80
TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother (2016) 0.80
Tumor-associated antigen specific CD8(+) T cells in hepatocellular carcinoma - a promising target for immunotherapy. Oncoimmunology (2014) 0.80
Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World J Gastroenterol (2016) 0.79
Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects. Immunotherapy (2014) 0.78
Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments. Cancer Manag Res (2017) 0.78
Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol (2016) 0.78
MicroRNA-491 regulates the proliferation and apoptosis of CD8(+) T cells. Sci Rep (2016) 0.77
Immunobiology of hepatocarcinogenesis: Ways to go or almost there? World J Gastrointest Pathophysiol (2016) 0.76
TAM receptor tyrosine kinase function and the immunopathology of liver disease. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
The altered glucose metabolism in tumor and a tumor acidic microenvironment associated with extracellular matrix metalloproteinase inducer and monocarboxylate transporters. Oncotarget (2016) 0.75
Identification of a FOXP3(+)CD3(+)CD56(+) population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma. Sci Rep (2015) 0.75
Hepatoma cell-derived leptin downregulates the immunosuppressive function of regulatory T-cells to enhance the anti-tumor activity of CD8(+) T-cells. Immunol Cell Biol (2015) 0.75
Variants identified by hepatocellular carcinoma and chronic hepatitis B virus infection susceptibility GWAS associated with survival in HBV-related hepatocellular carcinoma. PLoS One (2014) 0.75
Peripheral Blood Regulatory T-Cell and Type 1 Helper T-Cell Population Decrease after Hepatic Artery Embolization. J Vasc Interv Radiol (2016) 0.75
Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. Oncoimmunology (2016) 0.75
Tumor regulation of the tissue environment in the liver. Pharmacol Ther (2017) 0.75
Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future. Diseases (2016) 0.75
A different representation of natural T cells and natural killer cells between tumor-infiltrating and periphery lymphocytes in human hepatocellular carcinoma. Oncol Lett (2017) 0.75
Spontaneous CD4(+) and CD8(+) T cell responses directed against cancer testis antigens are present in the peripheral blood of testicular cancer patients. Eur J Immunol (2017) 0.75
Hepatocellular carcinoma. N Engl J Med (2011) 19.40
Cancer immunotherapy comes of age. Nature (2011) 12.35
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet (2000) 4.60
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology (2007) 3.34
T cell defined tumor antigens. Curr Opin Immunol (1997) 2.90
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Human TCR-binding affinity is governed by MHC class restriction. J Immunol (2007) 2.02
Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology (1998) 1.75
Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology (2009) 1.70
Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinoma. J Hepatol (2004) 1.56
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology (2009) 1.46
Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res (2006) 1.44
Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol (2012) 1.41
Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother (2010) 1.38
Natural T cell immunity against cancer. Clin Cancer Res (2003) 1.36
Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol (1998) 1.33
Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology (2011) 1.24
Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma. Hepatology (2008) 1.12
Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. J Clin Invest (2013) 1.10
Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol (2009) 1.09
Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology (2013) 1.03
The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res (2004) 0.98
Immunodominance across HLA polymorphism: implications for cancer immunotherapy. J Immunother (1998) 0.91
Expansion of interferon-gamma-producing multifunctional CD4+ T-cells and dysfunctional CD8+ T-cells by glypican-3 peptide library in hepatocellular carcinoma patients. Clin Immunol (2011) 0.88
Lack of ex vivo peripheral and intrahepatic α-fetoprotein-specific CD4+ responses in hepatocellular carcinoma. Int J Cancer (2011) 0.87
Low perforin expression of early differentiated HCV-specific CD8+ T cells limits their hepatotoxic potential. J Hepatol (2012) 0.86
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med (2006) 8.18
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol (2002) 6.69
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med (2007) 5.58
Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol (2003) 5.41
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22
HIV disease: fallout from a mucosal catastrophe? Nat Immunol (2006) 5.08
Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nat Med (2006) 4.41
Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood (2008) 4.34
Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology (2003) 4.13
T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol (2004) 4.02
An amino-terminal amphipathic alpha-helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J Biol Chem (2001) 3.91
Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med (2005) 3.63
Regulated expression of nuclear receptor RORγt confers distinct functional fates to NK cell receptor-expressing RORγt(+) innate lymphocytes. Immunity (2010) 3.59
Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol (2004) 3.39
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
The molecular basis for public T-cell responses? Nat Rev Immunol (2008) 3.32
Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med (2006) 3.26
CD8+ T cell efficacy in vaccination and disease. Nat Med (2008) 3.20
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol (2007) 3.18
Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 3.16
Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer (2006) 3.16
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95
SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. Blood (2007) 2.95
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog (2010) 2.91
Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem (2004) 2.71
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med (2008) 2.59
T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol (2005) 2.58
Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 2.57
The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol (2008) 2.44
Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood (2009) 2.33
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A (2002) 2.32
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology (2007) 2.25
A mechanism for TCR sharing between T cell subsets and individuals revealed by pyrosequencing. J Immunol (2011) 2.20
Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci U S A (2010) 2.19
Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett (2008) 2.17
Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med (2010) 2.17
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A (2005) 2.10
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood (2010) 2.06
A single autoimmune T cell receptor recognizes more than a million different peptides. J Biol Chem (2011) 2.06
Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest (2013) 2.06
NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood (2013) 2.04
Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. J Exp Med (2009) 2.03
Human TCR-binding affinity is governed by MHC class restriction. J Immunol (2007) 2.02
The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol (2004) 2.01
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood (2004) 2.01
Differential selection pressure exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the same HLA supertype. J Immunol (2006) 1.98
Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS. Proc Natl Acad Sci U S A (2004) 1.97
Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology (2006) 1.96
Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A (2004) 1.96
Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J Biol Chem (2007) 1.95
Impact of different crystalloid volume regimes on intestinal anastomotic stability. Ann Surg (2009) 1.95
Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat Immunol (2013) 1.95
Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. Nature (2011) 1.94
The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. J Biol Chem (2003) 1.92
Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem (2005) 1.92
Secondary graft failure and repeat endothelial keratoplasty after Descemet's stripping automated endothelial keratoplasty. Ophthalmology (2011) 1.84
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A (2010) 1.84
Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol (2002) 1.84
APOBEC-mediated interference with hepadnavirus production. Hepatology (2005) 1.82
On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds. Nat Chem Biol (2011) 1.82
Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol (2008) 1.79
Bias in the αβ T-cell repertoire: implications for disease pathogenesis and vaccination. Immunol Cell Biol (2011) 1.78
Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology (2009) 1.78
Malignant ascites: systematic review and guideline for treatment. Eur J Cancer (2006) 1.78